Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Oza, A Pignata, S Poveda, A McCormack, M Clamp, Andrew R Schwartz, B Cheng, J Li, X Campbell, K Dodion, P
Oza, A
Pignata, S
Poveda, A
McCormack, M
Clamp, Andrew R
Schwartz, B
Cheng, J
Li, X
Campbell, K
Dodion, P
Citations
Altmetric:
Abstract
The prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR) pathway is an important target, and mTOR inhibitors show clinical activity in endometrial cancer.
Description
Date
2015-06-15
Publisher
Collections
Keywords
Type
Article
Citation
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. 2015: J Clin Oncol